My review of C0nc0rdance

Orac (David H. Gorski) blogged:

(although we do have C0nc0rdance)

http://www.sciencebasedmedicine.org/index.php/three-myths-about-stanislaw-burzynski-and-the-skeptics

as if C0nc0rdance is a reliable source

1/24/2013 – C0nc0rdance posted a video on YouTube

The Burzynski Clinic

“Feel free to pass this on to anyone considering their options in alternative cancer treatments at the Burzynski Clinic

It’s also CCMA, so feel free to mirror or repost

AUTHOR’S NOTE:

I caught an error in post-production:

The Burzynski Clinic has only started 61 clinical trials, not 62

The last came up in my query because one of the authors has the same name

Otherwise the figures are correct”

“Fact 1:

The Burzynski Clinic has attempted 61 clinical trials, but only completed 1

Check it out here:”

http://www.clinicaltrials.gov/ct2/results?term=Burzynski&Search=Search

“Fact 2:

The Burzynski Clinic charges
its patients to participate in a study of their patented medication that exposes them to risk”

http://scienceblogs.com/insolence/2010/05/05/harnessing-peoples-good-to-pay-for-woo

“Fact 3:

The Burzynski Clinic makes heavy use of marketing techniques not normally associated with clinical practices and not in the best spirit of research medicine

For example, you can see here that they are abusing libel laws to silence critics”

http://www.guardian.co.uk/commentisfree/cifamerica/2011/nov/30/burzynski-clinic-cancer-libel-laws

And threatening and bullying of a 17 year old blogger by a media consultant:”

http://rhysmorgan.co/burzynski-morally-reprehensible

1:10-I want to present the case of Dr. Stanislaw Burzynski in my home state of Texas

1:30-cancer researcher

Maybe you should consider sticking to cancer research

1:32_3 red flags

Hearing this raised a “red flag” that your claims might be suspect

1:57_3 undisputed facts

And this proved it

2:00-Fact 1 clinical trials

The “FACT” one should know is that clinicaltrials . gov does NOT contain the same data as the National Cancer Institute (NCI) at the National Institutes of Health (NIH) cancer . gov web-site:

61 TOTAL
1 – Not Yet Recruiting (Open)(Phase 3)
1 – Closed
2 – Terminated (Withdrawn due to slow enrollment)
7 – Withdrawn (This study has been withdrawn prior to enrollment)
10 – Recruiting (Open)
11 – Open (1 Not Yet Recruiting / 10 Recruiting)
40 – Active, not recruiting (Closed)

http://cancer.gov/clinicaltrials/search/results?protocolsearchid=11475951

http://cancer.gov/clinicaltrials/search/results?protocolsearchid=11476036

On clinicaltrials . gov, if you select one of the “Unknowns,” it displays:

“Verified ____, ____ by National Cancer Institute (NCI)”

“Information provided by:
National Cancer Institute (NCI)”

“Further study details as provided by National Cancer Institute (NCI):”

Contact: Stanislaw R. Burzynski, MD, PhD

Investigators
Study Chair: Stanislaw R. Burzynski, MD, PhD

2:33-Every clinical trial has to register before starting

FALSE: I contacted the National Cancer Institute (NCI) at the National Institutes of Health (NIH) and was advised:

Not every cancer clinical trial taking place in the United States is listed on our NCI clinical trials database

The investigators must apply and follow guidelines to be included

4:08-Fact 2 – The Burzynski Clinic charges patients to receive clinical trial medications

FALSE: Burzynski does NOT charge for antineoplastons

By comparison:

St. Jude:

http://www.stjude.org/stjude/v/index.jsp?vgnextoid=403c6f9523e70110VgnVCM1000001e0215acRCRD

2/15/2012 – the U.S. Department of Health and Human Services has awarded St. Jude Children’s Research Hospital $4,314,800 for a childhood cancer survivor study

The new federal funds will be distributed by the National Cancer Institute (NCI)

http://cohen.house.gov/press-release/cohen-st-jude-receive-43-million-childhood-cancer-survivor-study

Tax-Exempt
Receives Federal Grants / Funds

http://www.stjude.org/stjude/v/index.jsp?vgnextoid=b7e79bb8a0cf5110VgnVCM1000001e0215acRCRD&cpsextcurrchannel=1

Donations to St. Jude are tax deductible as allowed by law

http://www.stjude.org/stjude/v/index.jsp?vgnextoid=6f8afa3186e70110VgnVCM1000001e0215acRCRD&vgnextchannel=2f62940504f9a210VgnVCM1000001e0215acRCRD

FORBES: CEO – $742,718

http://www.forbes.com/fdc/welcome_mjx.shtml

Burzynski does NOT receive Federal Grants / Funds, is NOT Tax-Exempt, and you can NOT write off a contribution as a tax deduction on your Tax Return

6:32-Burzynski movie
doesn’t examine the issue from both sides

FACT: None of the oncologists who originally diagnosed each patient presented in this film would agree to go on-camera, or submit a written statement
1:44:44 – 1:44:52
(http://www.burzynskimovie.com)

6:41-Conspiracy

FACT: See these 2 links:

http://burzynskimovie.com/images/stories/transcript/Documents/BurzynskiTriesToExposeNCI.pdf

http://stanislawrajmundburzynski.wiki-site.com/index.php/Main_Page

Fact 3: it is referred to as “Beating a Dead Horse” when a point that is moot, is be labored by critics

About these ads

13 thoughts on “My review of C0nc0rdance

  1. This is a useless response. You address “fact 1″ by pointing to a website which simply states that the status of most of the trials is unknown. That is a useless designation that does nothing to disprove the fact that of the 61 studies you have conducted, only 1 has ever reported results. Do you deny this fact? Do you have an explanation for it?

    You try to deflect the question by linking to another website, reporting the same information (cancer.gov). But as it says on that very site:

    Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials.

    The only advantage to going to the cancer.gov site you recommend over the clinicaltrials.gov site is that the former doesn’t list completed trials.

    Then you say that not all studies have been registered. That doesn’t help your case. If you have concluded trials and not registered them, please show us where we can access their peer-reviewed results.

    You justify your outrageously high costs (typically many tens of thousands of dollars) to participate in clinical trials by pointing out that some other research institutes receive money from federal and private grants, tax exemption, and private donations. Again, this does not help your case. Clearly, such a source of funding is far preferable to the way Burzynski trials are funded, by the participants. Additionally, your inability to get grants for an allegedly life-saving cancer cure is indicative of flawed methodology or just a lack of efficacy.

    Furthermore, most drug trials are largely funded by the companies intended to sell the drugs. If you intend to profit off an approved drug, you should be willing to make an investment or get other investors for real science. But instead you are profiting off the trials themselves, which have been recruiting endlessly and never report results. It shouldn’t even be legal.

    Your evidence of a scientific conspiracy against your work is not evidence at all. It consists of a letter written by Burzynski and a disorganized list of links showing various NCI agreements spanning more than three decades. Your definitions of “advanced cancer” were not in accordance with standard definitions, and when the NCI tried to correct this, you painted it as persecution. You obliquely reference tumors shrinking by more than 50%, but show no evidence that any performed better than control. And you make wild claims about what the NCI’s (accurate) report on your seven best cases is “calculated to make the reader think,” rather than respond to the actual facts it determined.

    But what disgusts me the most is your response to Fact 3. You do not deny that your clinic attempted to bully numerous critics into silence by abusing libel laws. To my knowledge, you have never recognized or apologized for this reprehensible and repeat activity which is antithetical to the scientific method. You even attempted to silence C0nc0rdnace when he made this video, filing a DMCA complaint on illegitimate grounds (and potentially committing a felony in the process), removing his video, and quibbling over a single low-res image that qualifies as fair use. Will you make no attempt to justify or apologize for this behavior, or will you just sweep it under the rug?

    • Michael has replied to your comment on Burzynski, skepticism, false DMCAs and the Streisand effect – mirrored for C0nc0rdance

      I made a nice reply to your “review”.

      I’m sure it will be approved soon, right?

      It sure will, because unlike Dr. Peter A. Lipson and / or his Censor(s), Dr. David A. Gorski, Adam Jacobs, Kier Liddle, _Josephine Jones, etc., I do NOT censor, because I actually believe in “Free Speech”

      “This is a useless response”

      REALLY ?

      “You address “fact 1″ by pointing to a website which simply states that the status of most of the trials is unknown”

      SERIOUSLY ?

      My review of C0nc0rdance | Didymus Judas Thomas’ Hipocritical Oath Blog
      https://stanislawrajmundburzynski.wordpress.com/2013/03/23/my-review-of-c0nc0rdance
      Let’s review together, shall we?

      (c0nc0rdance video)

      2:00-Fact 1 clinical trials

      The “FACT” one should know is that clinicaltrials . gov does NOT contain the same data as the National Cancer Institute (NCI) at the National Institutes of Health (NIH) cancer . gov web-site:

      61 TOTAL
      1 – Not Yet Recruiting (Open)(Phase 3)
      1 – Closed
      2 – Terminated (Withdrawn due to slow enrollment)
      7 – Withdrawn (This study has been withdrawn prior to enrollment)
      10 – Recruiting (Open)
      11 – Open (1 Not Yet Recruiting / 10 Recruiting)
      40 – Active, not recruiting (Closed)

      (I added this in “parenthesis”)
      The below 1 st link: 10 Active (Open):
      http://cancer.gov/clinicaltrials/search/results?protocolsearchid=11475951
      (I added this in “parenthesis”)
      The below 2nd link: 25 Closed-1st screen / 15 Closed-1 Completed-2nd screen:
      http://cancer.gov/clinicaltrials/search/results?protocolsearchid=11476036
      NONE of the above are “UNKNOWN” per the above 2 National Cancer Institute (NCI) at the National Institutes of Health (NIH) links

      10 – Recruiting (Open)
      11 – Open (1 Not Yet Recruiting / 10 Recruiting)
      40 – Active, not recruiting (Closed)

      10=Open
      11=1 Not Yet Recruiting / 10 Recruiting
      40=Closed
      61-TOTAL

      “That is a useless designation that does nothing to disprove the fact that of the 61 studies you have conducted, only 1 has ever reported results”

      “I” have NOT conducted ANY studies because “I” am NOT Burzynski; a fact you would known if you had “researched” it

      Ever heard the saying:

      “When you ASSume, you make an ASS out of you and me?

      “Do you deny this fact?”

      Yes, do you deny this fact?

      “Do you have an explanation for it?”

      An explanation for what?

      The above information I provided previously is still correct:

      The above 1 st link: 10 Active (Open):
      The above 2nd link: 25 Closed-1st screen / 15 Closed-1 Completed-2nd screen

      “You try to deflect the question by linking to another website, reporting the same information (cancer.gov). But as it says on that very site:”

      “Information about this trial is from the ClinicalTrials.gov database.”

      “The versions designated for health professionals and patients contain the same text.”

      “Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts.”

      “Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials.”

      “The only advantage to going to the cancer.gov site you recommend over the clinicaltrials.gov site is that the former doesn’t list completed trials.”

      WHATEVER !!

      And you are a “researcher” ?

      “Then you say that not all studies have been registered.”

      SURE ?

      FALSE: I contacted the National Cancer Institute (NCI) at the National Institutes of Health (NIH) and was advised:

      Not every cancer clinical trial taking place in the United States is listed on our NCI clinical trials database

      “That doesn’t help your case.”

      That does NOT hurt my case

      ” If you have concluded trials and not registered them, please show us where we can access their peer-reviewed results.”

      Would you like to see what I have posted on my blog?

      This link reflects:

      11/25/1997 – Filing Date: FORM 10-SB

      11/25/1997 – Company sponsoring 72 Phase II clinical trials conducted pursuant to INDs filed with FDA which are currently ongoing

      And it lists the 72 clinical trials

      Burzynski Clinical Trials (The SEC filings) | Didymus Judas Thomas’ Hipocritical Oath Blog
      https://stanislawrajmundburzynski.wordpress.com/2013/04/11/burzynski-clinical-trials-2
      “You justify your outrageously high costs (typically many tens of thousands of dollars) to participate in clinical trials by pointing out that some other research institutes receive money from federal and private grants, tax exemption, and private donations.”

      Well, NO I do NOT, because I am NOT “You”

      “Again, this does not help your case. Clearly, such a source of funding is far preferable to the way Burzynski trials are funded, by the participants.”

      What evidence do you have that Burzynski has or has NOT attempted to:

      “receive money from federal and private grants, tax exemption, and private donations.”?

      “Additionally, your inability to get grants for an allegedly life-saving cancer cure is indicative of flawed methodology or just a lack of efficacy.”

      NOPE, NOT “your”

      What evidence do you have that Burzynski has or has NOT attempted:

      “to get grants for an allegedly life-saving cancer cure”?

      “Furthermore, most drug trials are largely funded by the companies intended to sell the drugs.”

      And how big are those “companies” as far as net worth?

      “If you intend to profit off an approved drug, you should be willing to make an investment or get other investors for real science.

      What evidence do you have that Burzynski has or has NOT attempted

      “to make an investment or get other investors for real science.?”

      Have you read his Securities and Exchange Commission filings like I have?

      “But instead you are profiting off the trials themselves, which have been recruiting endlessly and never report results. It shouldn’t even be legal.”

      NO, “you” is NOT profiting

      Have you read his Securities and Exchange Commission filings like I have?

      Burzynski (The SEC filings) | Didymus Judas Thomas’ Hipocritical Oath Blog
      https://stanislawrajmundburzynski.wordpress.com/2013/04/16/burzynski-the-sec-filings

      “Your evidence of a scientific conspiracy against your work is not evidence at all.”

      “It consists of a letter written by Burzynski and a disorganized list of links showing various NCI agreements spanning more than three decades.”

      (c0nc0rdance video)

      6:41-Conspiracy

      POSITIVE ?

      Let’s review the links I provided, shall we?

      FACT: See these 2 links:
      http://burzynskimovie.com/images/stories/transcript/Documents/BurzynskiTriesToExposeNCI.pdf

      http://stanislawrajmundburzynski.wiki-site.com/index.php/Main_Page
      10/2/1991
      11/2/1993
      3/1/1994
      3/23/1994
      4/19/1994
      1/31/1995
      4/3/1995
      8/23/1995
      9/19/1995
      10/5/1995
      10/25/1995
      10/27/1995

      10/2/1991-10/27/1995 is NOT

      “spanning more than three decades.”

      “Your definitions of “advanced cancer” were not in accordance with standard definitions, and when the NCI tried to correct this, you painted it as persecution.”

      Nada, “Your”

      You will need to do better than this with what Americans consider appropriate “citation(s),” “reference(s), and / or “link(s)”

      “You obliquely reference tumors shrinking by more than 50%, but show no evidence that any performed better than control.”

      Zip, NOT “You”

      See above

      “And you make wild claims about what the NCI’s (accurate) report on your seven best cases is “calculated to make the reader think,” rather than respond to the actual facts it determined.”

      No, “you” did NOT “make wild claims,” since I am NOT “you”

      See above

      “But what disgusts me the most is your response to Fact 3.”

      “You do not deny that your clinic attempted to bully numerous critics into silence by abusing libel laws.”

      Nice try, but NOT “your clinic”

      Take it up with the person responsible

      “To my knowledge, you have never recognized or apologized for this reprehensible and repeat activity which is antithetical to the scientific method.”

      And “I” will NOT, since I ain’t (that’s a “Texas” word) “you”

      “You even attempted to silence C0nc0rdnace when he made this video, filing a DMCA complaint on illegitimate grounds (and potentially committing a felony in the process), removing his video, and quibbling over a single low-res image that qualifies as fair use.”

      So, now I am Eric Merola ?

      Try again, buckaroo

      “Will you make no attempt to justify or apologize for this behavior, or will you just sweep it under the rug?”

      Will you make no attempt to justify or apologize for this behavior, or will you just sweep it under the rug?

      Michael has replied to your comment on The Burzynski Clinic

      “It may not charge for the “antineoplastons”, but it charges for genetic “testing” that does absolutely nothing.

      (c0nc0rdance video)

      4:08-Fact 2 – The Burzynski Clinic charges patients to receive clinical trial medications

      FALSE: Burzynski does NOT charge for antineoplastons

      PROVE IT

      “Do you dispute that people who want to participate in your trials must raise en”
      http://m.youtube.com/#/inbox?feature=em-comment_reply_received&desktop_uri=%2Finbox%3Ffeature%3Dem-comment_reply_received
      WOT ?

      I refer you to the statement I made in my “review” in re me being “Burzynski” or “Merola:”

      Fact 3: it is referred to as “Beating a Dead Horse” when a point that is moot, is be labored by critics

      • The “FACT” one should know is that clinicaltrials . gov does NOT contain the same data as the National Cancer Institute (NCI) at the National Institutes of Health (NIH) cancer . gov web-site:

        And yet the site itself claims the information is the same. The difference, as I stated, is that the NCI site only lists open trials.

        You have not addressed my question. You say you dispute that only one study out of the 61 has reported results. You seem to agree that the 61 total is correct, so it seems you are claiming that more than one has reported results. In fact, I was giving you the benefit of the doubt here. Upon closer inspection, none of the 61 trials have been published; however, one was concluded. Many more are still active or have been withdrawn. This is a pitiful number.

        Please do not repeat those same statistics again. Simply conducting a study and labeling it as perpetually “active” (but closed) is not a result. Please provide a source showing any published studies.

        “I” have NOT conducted ANY studies because “I” am NOT Burzynski; a fact you would known if you had “researched” it

        As far as I can tell, I have no way of knowing this. You don’t sign your name anywhere, blog under a pseudonym, and have a blank “About” page. Since the blog’s name is “stanislawrajmundburzynski,” I’m sure you will forgive my confusion.

        I wouldn’t think this was a big deal, except you seem to use my incorrect pronoun as an excuse to disregard large portions of my text. I’m sorry I confused you with someone else, but that has no bearing on the truth of my arguments. And to be clear, I did not think you were Dr. Burzynski himself. When I referred to “you,” I mean “you” in the general sense of your company. If you are not affiliated, then again, that’s just a mistake.

        This link reflects:

        11/25/1997 – Filing Date: FORM 10-SB

        11/25/1997 – Company sponsoring 72 Phase II clinical trials conducted pursuant to INDs filed with FDA which are currently ongoing

        And it lists the 72 clinical trials

        Those are not results. Those are ongoing studies. I am asking for results of concluded studies. I don’t know why these are difficult to procure.

        As I understand it, Dr. Burzynski has been performing trials for nearly forty years, and has never published results demonstrating the efficacy of his treatment in a peer-reviewed journal. If I am mistaken, please direct me to the publication. Please stop listing registration for studies as if that were a result.

        What evidence do you have that Burzynski has or has NOT attempted to:

        “receive money from federal and private grants, tax exemption, and private donations.”?

        I do not suggest that he has not applied for grants, and I am sure he has accepted donations. However, it appears he has not received grant money. As I said, being unable to procure grants is evidence of an ineffective or unproven treatment, not evidence of persecution. Furthermore, he cannot have tax-exempt status, because his clinics turn a profit.

        What evidence do you have that Burzynski has or has NOT attempted

        “to make an investment or get other investors for real science.?”

        Have you read his Securities and Exchange Commission filings like I have?

        Again, it feels like you are deliberately misreading me. I never suggested he had not made these attempts. I do not care what he has “tried” to do. The fact is he has not done so. As I have said, passing the cost on to his patients is not an acceptable alternative. It seems he has turned to both private and public sources and not received support for his unproven treatments, so instead he draws the support from the most vulnerable.

        FALSE: Burzynski does NOT charge for antineoplastons

        According to the ACS, “Antineoplastons are given by mouth, injection into a vein or muscle, and by other routes. The treatment usually lasts from 8 – 12 months. Treatment can cost from $7,000 to $9,500 per month or more . . . .”

        Here is a reprint of parts of a page curiously removed from the internet, telling the story of one patient whose Burzynski trial drugs cost in excess of $4k a month each.

        Either way, the point is moot. In order to enroll in these studies, you must receive your cancer treatment from the Burzynski Clinic, and that clinic charges around $7500 a month for chemotherapy for a typical patient.

        I would like to note that you failed to respond in any substantive fashion to the claims that:
        1. There are no peer-reviewed results of Dr. Burzynski’s many trials.
        2. At least 61 trials have been registered.
        3. The evidence you presented for a conspiracy against Dr. Burzynski’s work is nothing of the sort.
        3a. Specifically that Dr. Burzynski used inappropriate definitions for “advanced cancer.”
        4. Eric Merola has on a number of occasions abused libel and copyright law to suppress criticism online.

      • “The U.S. v. Article’~ court stated that the FDA’s responsibility was to protect the ultimate consumer, which included protection of “the ignorant, the unthinking and the credulous.”‘

        Right now I am one of the “credulous”

        Please let me know if you fit into one of the above categories

        So, “Orac” requested that I comment on the video:

        #6 – Didymus Judas Thomas – At the Tu-Quack Center IMAX 3-D Video Viewing Velodrome – January 28, 2013

        …and then (ahem) “C0nc0rdance” commented:

        #49 – c0nc0rdance – January 29, 2013
        @Orac
        “Many, many thanks for sharing my video.)…”
        http://scienceblogs.com/insolence/2013/01/28/an-excellent-explanation-of-how-dubious-stanislaw-burzynskis-activities-are/
        “And yet the site itself claims the information is the same.”

        “The difference, as I stated, is that the NCI site only lists open trials.”

        And this is why I am “credulous”

        Would you like the opportunity to again read my previous reply to you and select the 2nd link I provided?

        Because this type of situation sort of reminds me of “Orac,” Guy Chapman, Boris Ogon, Wikipedia, etc., in that they use this tactic of posting a lot, instead of dealing with one issue at a time

        They should really learn to deal with one issue at a time instead of trying the “scattergun” approach, unless a consensus is made by all parties to “agree to disagree”

        “…the NCI site only lists open trials.”

        Did you select the 2nd link I provided and view the trials which were NOT open?

  2. What is your point? I am quoting the website directly. If you think their words are in error, take it up with them.

    They say they only list sites that are actively recruiting. The Burzynski Clinic is actively recruiting, so maybe they include all their trials, including the ones that have now closed. Or maybe they include all active trials (whether or not they are still recruiting), and just not those that have been concluded or withdrawn.

    Either way, there is nothing to be gained by going to cancer.gov over clinicialtrials.gov.

    And either way, this is a microscopic issue, irrelevant to the main point of your blog or C0nc0rdance’s video. Why do you keep distracting from the main points, like those I listed at the bottom of my post?

      • I have followed all the links you have provided.

        Are you going to address the questions, or just pretend they don’t exist?

      • Michael on April 29, 2013 at 2:07 pm

        “I have followed all the links you have provided.”

        “Are you going to address the questions, or just pretend they don’t exist?”

        Michael, now that I have dealt with the issue of Forbes censoring (deleting) comments, and the BIAS of their article, and “Orac” and “The Skeptic” “Oracolytes,” I now have time to address your comments, again

        “Michael on April 28, 2013 at 7:54 pm”

        “What is your point?”

        My point is that I covered this in detail in my original review article:

        My review of C0nc0rdance:
        https://stanislawrajmundburzynski.wordpress.com/2013/03/23/my-review-of-c0nc0rdance
        “I am quoting the website directly.”

        And “I am quoting the website directly:”

        On clinicaltrials . gov, if you select one of the “Unknowns,” it displays:

        “Verified ____, ____ by National Cancer Institute (NCI)”

        “Information provided by:
        National Cancer Institute (NCI)”

        “Further study details as provided by National Cancer Institute (NCI):”

        “If you think their words are in error, take it up with them.”

        And my reply is:

        “If you think their words are in error, take it up with them.”

        “They say they only list sites that are actively recruiting.”

        And you said:

        “Michael on April 29, 2013 at 2:07 pm”

        “I have followed all the links you have provided.”

        So, I take it that you found out that the info. I provided is correct

        “The Burzynski Clinic is actively recruiting, so maybe they include all their trials, including the ones that have now closed.”

        “Or maybe they include all active trials (whether or not they are still recruiting), and just not those that have been concluded or withdrawn.”

        “Either way, there is nothing to be gained by going to cancer.gov over clinicialtrials.gov.”

        “And either way, this is a microscopic issue, irrelevant to the main point of your blog or C0nc0rdance’s video.”

        “Why do you keep distracting from the main points, like those I listed at the bottom of my post?”

        It’s not distraction when you kept distracting from the main points, like those I listed throughout my post

        Michael on April 28, 2013 at 2:10 am

        The “FACT” one should know is that clinicaltrials . gov does NOT contain the same data as the National Cancer Institute (NCI) at the National Institutes of Health (NIH) cancer . gov web-site:

        “And yet the site itself claims the information is the same.”

        “The difference, as I stated, is that the NCI site only lists open trials.”

        “You have not addressed my question.”

        “You say you dispute that only one study out of the 61 has reported results.”

        Is THAT really what I said I “dispute”?

        “You seem to agree that the 61 total is correct, so it seems you are claiming that more than one has reported results.”

        Is THAT really what I am “claiming”?

        “In fact, I was giving you the benefit of the doubt here.”

        “Upon closer inspection, none of the 61 trials have been published; however, one was concluded.”

        Amazingly, as many times as “Orac” and “The Skeptic” “Oracolytes” mention this “one” concluded (or “completed”) trial, they seem to be unable to cite the date it was “completed”

        From the previous links I provided, this one lists the “one” completed trial:

        The below 2nd link: 25 Closed-1st screen / 15 Closed-1 Completed-2nd screen:
        http://cancer.gov/clinicaltrials/search/results?protocolsearchid=11476036
        Antineoplaston Therapy in Treating Patients With Stage IV Melanoma

        Phase: Phase II
        Type: Treatment
        Status: Completed
        Age: 18 and over
        Sponsor: Other
        Protocol IDs: CDR0000066552, BC-ME-2, NCT00003509

        From the Securities and Exchange Commission (SEC) filings we can find this “one” completed trial:

        Burzynski Clinical Trials (The SEC filings):
        https://stanislawrajmundburzynski.wordpress.com/2013/04/11/burzynski-clinical-trials-2/
        Certain prospective protocols which have reached a Milestone as of May 1, 2012

        Antineoplaston Therapy in Treating Patients With Stage IV Melanomau
        Melanoma (Skin)
        Drug: antineoplaston A10
        Drug: antineoplaston AS2-1
        Phase 2
        Phase II
        COMPLETED
        Age 18 and over
        Protocol IDs
        CDR0000066552
        BC-ME-2, NCT00003509
        http://cancer.gov/clinicaltrials/BC-ME-2
        COMPLETED

        Antineoplaston Therapy in Treating Patients With Stage IV Melanoma

        Basic Trial Information
        Trial Description
        Summary
        Further Trial Information
        Eligibility Criteria
        Trial Contact Information

        Basic Trial Information
        Phase Phase II
        Type Treatment
        Status Completed
        Age 18 and over
        Sponsor Other
        Protocol IDs CDR0000066552
        BC-ME-2, NCT00003509

        Trial Description
        Summary
        RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the laboratory

        Antineoplastons may inhibit the growth of cancer cells

        PURPOSE: This phase II trial is studying how well antineoplaston therapy works in treating patients with progressive or recurrent stage IV melanoma

        Further Study Information
        OBJECTIVES: Determine the safety and possible effectiveness of antineoplastons A10 and AS2-1 in patients with progressive or recurrent stage IV melanoma

        Describe response, tolerance to, and side effects of this regimen in these patients

        OUTLINE: This is an open label study

        Patients receive gradually escalating doses of antineoplaston A10 and antineoplaston AS2-1 by intravenous injection 6 times daily until the maximum tolerated dose is reached

        Treatment continues for at least 3 months in the absence of toxicity and disease progression

        Patients achieving complete response (CR) continue treatment for an additional 8 months after reaching CR

        Tumors are measured every 2 months for the first year and every 3 months for the second year

        PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study

        Eligibility Criteria
        DISEASE CHARACTERISTICS: Histologically confirmed stage IV melanoma that is recurrent or progressing and unlikely to respond to existing therapy

        Measurable disease by MRI or CT scan
        Tumor must be at least 2 cm in the lymph nodes in the head, neck, axillary, inguinal, or femoral areas and at least 0.5 cm in other locations

        PATIENT CHARACTERISTICS:
        Age: 18 and over

        Performance status: Karnofsky 60-100%

        Life expectancy: At least 2 months

        Hematopoietic: WBC at least 2,000/mm3

        Platelet count at least 50,000/mm3

        Hepatic: Bilirubin no greater than 2.5 mg/dL

        SGOT and SGPT no greater than 5 times the upper limit of normal

        No hepatic insufficiency

        Renal: Creatinine no greater than 2.5 mg/dL

        No renal insufficiency

        No renal conditions that contraindicate high dosages of sodium

        Cardiovascular: No chronic heart failure

        No uncontrolled hypertension

        No history of congestive heart failure

        No other cardiovascular conditions that contraindicate high dosages of sodium

        Pulmonary: No severe lung disease, such as chronic obstructive pulmonary disease

        Other: Not pregnant or nursing

        Fertile patients must use effective contraception during and for 4 weeks after study

        No serious medical or psychiatric disorders

        No active infection

        PRIOR CONCURRENT THERAPY:
        Biologic therapy: At least 4 weeks since prior immunotherapy and recovered

        No concurrent immunomodulating agents

        Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered

        No concurrent antineoplastic agents

        Endocrine therapy: Concurrent corticosteroids allowed

        Radiotherapy: At least 8 weeks since prior radiotherapy and recovered

        (patients with multiple tumors who have received radiotherapy to some, but not all, tumors may be admitted earlier than 8 weeks)

        Surgery: Recovered from prior surgery

        Other: Prior cytodifferentiating agent allowed

        No prior antineoplaston therapy

        Trial Contact Information
        Trial Lead Organizations/Sponsors
        Burzynski Clinic
        Stanislaw R. Burzynski Study Chair

        Link to the current ClinicalTrials.gov record
        NLM Identifer NCT00003509

        Information obtained from ClinicalTrials.gov on November 20, 2012

        Note: Information about this trial is from the ClinicalTrials.gov database

        The versions designated for health professionals and patients contain the same text

        Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts

        Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials

        Questions and comments regarding the presented information should be directed to ClinicalTrials.gov

        A search of ClinicalTrials . gov displays:
        http://clinicaltrials.gov/ct2/results?term=&recr=Completed&rslt=&type=&cond=&intr=&titles=&outc=&spons=&lead=Burzynski+&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&phase=1&rcv_s=&rcv_e=&lup_s=&lup_e=
        Completed

        Antineoplaston Therapy in Treating Patients With Stage IV Melanoma

        Condition: Melanoma (Skin)

        Interventions:
        Drug: antineoplaston A10;
        Drug: antineoplaston AS2-1

        1 study: Melanoma
        1 study: Neoplasms, Germ Cell and Embryonal
        1 study: Neoplasms, Nerve Tissue
        1 study: Neuroectodermal Tumors
        1 study: Neuroendocrine Tumors
        1 study: Neuroepithelioma
        1 study: Nevus
        1 study: Nevus, Pigmented

        1 study found, shown on map

        Region Number of
        Name Studies
        World 1
        North America 1
        United States [map] 1 [studies]

        Found 1 study with search of: Completed | Burzynski [Lead] | Phase 2

        Recognized Terms and Synonyms:
        burzynski: 61 studies
        http://clinicaltrials.gov/ct2/show/NCT00003509?recr=Completed&lead=Burzynski&phase=1&rank=1
        Trial record 1 of 1 for: Completed | Burzynski [Lead] | Phase 2

        Antineoplaston Therapy in Treating Patients With Stage IV Melanoma

        This study has been completed

        Sponsor: Burzynski Research Institute

        Information provided by:
        National Cancer Institute (NCI)

        ClinicalTrials.gov Identifier: NCT00003509

        First received: November 1, 1999

        Last updated: May 23, 2009

        Last verified: May 2009
        http://clinicaltrials.gov/ct2/archive/NCT00003509
        History of Changes

        Purpose:

        Detailed Description:

        Criteria

        Contacts and Locations

        Locations: United States, Texas
        Burzynski Clinic
        Houston, Texas, United States

        Trial Contact Information
        Trial Lead Organizations/Sponsors
        Burzynski Clinic
        Stanislaw R. Burzynski Study Chair

        Link to the current ClinicalTrials.gov record
        NLM Identifer NCT00003509

        Information obtained from ClinicalTrials.gov on November 20, 2012

        Note: Information about this trial is from the ClinicalTrials.gov database

        The versions designated for health professionals and patients contain the same text

        Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts

        Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials

        Questions and comments regarding the presented information should be directed to ClinicalTrials.gov

        Condition Melanoma (Skin)
        Intervention
        Drug: antineoplaston A10
        Drug: antineoplaston AS2-1
        Phase: Phase 2

        Study Type: Interventional
        Study Design: Masking: Open Label
        Primary Purpose: Treatment
        Official Title: Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Malignant Melanoma

        Resource links provided by NLM:

        MedlinePlus related topics: Cancer Melanoma
        U.S. FDA Resources

        Further study details as provided by National Cancer Institute (NCI):

        Primary Outcome Measures: Response rate based on tumor measurements at 12 weeks [ Designated as safety issue: No ]

        Secondary Outcome Measures:
        Survival at 1, 2, and 5 years from the start of treatment [ Designated as safety issue: No ]

        Estimated Enrollment: 40

        Study Start Date: March 1996

        Primary Completion Date: February 2005 (Final data collection date for primary outcome measure)

        Detailed Description:
        OBJECTIVES: Determine the safety and possible effectiveness of antineoplastons A10 and AS2-1 in patients with progressive or recurrent stage IV melanoma

        Describe response, tolerance to, and side effects of this regimen in these patients

        OUTLINE: This is an open label study

        Patients receive gradually escalating doses of antineoplaston A10 and antineoplaston AS2-1 by intravenous injection 6 times daily until the maximum tolerated dose is reached

        Treatment continues for at least 3 months in the absence of toxicity and disease progression

        Patients achieving complete response (CR) continue treatment for an additional 8 months after reaching CR

        Tumors are measured every 2 months for the first year and every 3 months for the second year

        PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study

        Eligibility
        Ages Eligible for Study: 18 Years and older

        Genders Eligible for Study: Both

        Accepts Healthy Volunteers: No

        Criteria
        DISEASE CHARACTERISTICS: Histologically confirmed stage IV melanoma that is recurrent or progressing and unlikely to respond to existing therapy

        Measurable disease by MRI or CT scan

        Tumor must be at least 2 cm in the lymph nodes in the head, neck, axillary, inguinal, or femoral areas and at least 0.5 cm in other locations

        PATIENT CHARACTERISTICS:
        Age: 18 and over

        Performance status: Karnofsky 60-100%

        Life expectancy: At least 2 months

        Hematopoietic: WBC at least 2,000/mm3

        Platelet count at least 50,000/mm3

        Hepatic: Bilirubin no greater than 2.5 mg/dL

        SGOT and SGPT no greater than 5 times the upper limit of normal

        No hepatic insufficiency

        Renal: Creatinine no greater than 2.5 mg/dL

        No renal insufficiency

        No renal conditions that contraindicate high dosages of sodium

        Cardiovascular: No chronic heart failure

        No uncontrolled hypertension

        No history of congestive heart failure

        No other cardiovascular conditions that contraindicate high dosages of sodium

        Pulmonary: No severe lung disease, such as chronic obstructive pulmonary disease

        Other: Not pregnant or nursing

        Fertile patients must use effective contraception during and for 4 weeks after study

        No serious medical or psychiatric disorders

        No active infection

        PRIOR CONCURRENT THERAPY:
        Biologic therapy: At least 4 weeks since prior immunotherapy and recovered

        No concurrent immunomodulating agents

        Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered

        No concurrent antineoplastic agents

        Endocrine therapy: Concurrent corticosteroids allowed

        Radiotherapy: At least 8 weeks since prior radiotherapy and recovered

        (patients with multiple tumors who have received radiotherapy to some, but not all, tumors may be admitted earlier than 8 weeks)

        Surgery: Recovered from prior surgery

        Other: Prior cytodifferentiating agent allowed

        No prior antineoplaston therapy

        Contacts and Locations
        Please refer to this study by its ClinicalTrials.gov identifier: NCT00003509

        Locations: United States, Texas
        Burzynski Clinic
        Houston, Texas, United States

        Sponsors and Collaborators: Burzynski Research Institute

        Investigators: Study Chair: Stanislaw R. Burzynski, MD, PhD Burzynski Research Institute

        More Information
        Additional Information: Clinical trial summary from the National Cancer Institute’s PDQ® database

        No publications provided

        Responsible Party: Stanislaw R. Burzynski, Burzynski Clinic

        ClinicalTrials.gov Identifier: NCT00003509

        History of Changes

        Other Study ID Numbers: CDR0000066552, BC-ME-2

        Study First Received: November 1, 1999

        Health Authority: United States: Federal Government

        Keywords provided by National Cancer Institute (NCI):
        stage IV melanoma
        recurrent melanoma

        Additional relevant MeSH terms:
        Melanoma
        Neuroendocrine Tumors
        Neuroectodermal Tumors
        Neoplasms, Germ Cell and Embryonal
        Neoplasms by Histologic Type
        Neoplasms
        Neoplasms, Nerve Tissue
        Nevi and Melanomas

        ClinicalTrials.gov processed this record on May 06, 2013

        Antineoplaston Therapy in Treating Patients With Stage IV Melanoma

        This study has been completed

        Sponsors: Burzynski Research Institute

        Information provided by: National Cancer Institute (NCI)

        ClinicalTrials.gov Identifier: NCT00003509

        History of Changes

        PURPOSE: This phase II trial is studying how well antineoplaston therapy works in treating patients with progressive or recurrent stage IV melanoma

        Condition Intervention Phase
        Melanoma (Skin)
        Drug: antineoplaston A10
        Drug: antineoplaston AS2-1
        Phase 2

        Study Type: Interventional
        Study Design: Masking: Open Label
        Primary Purpose: Treatment
        Official Title: Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Malignant Melanoma

        Resource links provided by NLM:

        MedlinePlus related topics: Cancer Melanoma
        U.S. FDA Resources

        History of Changes and the ClinicalTrials.gov Archive Site

        Information in a ClinicalTrials.gov record can be modified at any time by the data provider

        The display at ClinicalTrials.gov shows the most recent version for each data element

        The date first received and the date last updated are listed at the top of each record

        The full history of changes since the record was first received is available in the archival version of the record on the ClinicalTrials.gov Archive Site

        Current Study:
        ClinicalTrials.gov Identifier: NCT00003509

        Study Title: Antineoplaston Therapy in Treating Patients With Stage IV Melanoma

        First Received: November 1, 1999

        Continue to the history of changes for this study on the ClinicalTrials.gov Archive Site
        http://clinicaltrials.gov/archive/NCT00003509
        History of NCT00003509

        Brief title: Antineoplaston Therapy in Treating Patients With Stage IV Melanoma

        Record State: RELEASED

        Updated View Type of info changed
        2005_06_23 Study Nothing (earliest version on record)

        2005_06_30 Study Changes Misc.
        1 clinical_study see_also
        2
        initial_release_date 1999-11-01

        last_release_date 2005-06-23
        3 clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2005_06_30/changes
        2005_07_25 Study Changes Protocol
        1 clinical_study textblock
        2
        Fm: Antineoplaston Therapy in Treating Patients With Stage IV Melanoma
        To: Antineoplaston Therapy in Treating Patients with Stage IV Melanoma
        3 textblock. clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2005_07_25/changes
        2005_08_01 Study Changes Protocol
        1 clinical_study textblock
        2
        Fm: Antineoplaston Therapy in Treating Patients with Stage IV Melanoma
        To: Antineoplaston Therapy in Treating Patients With Stage IV Melanoma
        3 textblock clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2005_08_01/changes
        2005_09_09 Study Changes Administrative, Misc.
        1 clinical_study secondary_id
        2 Deleted: secondary_id. NCT00003509
        3 nct_id last_release_date
        4
        Fm: 2005-06-23
        To: 2005-09-08
        5 last_release_date clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2005_09_09/changes
        2005_12_08 Study Changes Protocol
        1 clinical_study textblock
        2
        Fm: Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Stage IV Melanoma
        To: Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Stage IV Melanoma
        3 textblock clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2005_12_08/changes
        2006_03_30 Study Changes Protocol, Misc.
        1 clinical_study primary_name
        2
        Fm: biological response modifier therapy
        To: biological therapy
        Fm: 2005-09-08
        To: 2006-03-29
        3 primary_name last_release_date
        4
        Fm: 2005-09-08
        To: 2006-03-29
        5 last_release_date clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2006_03_30/changes
        2006_05_23 Study Changes Recruitment, Misc.
        1 clinical_study date
        2
        Fm: 1998-12
        To: 2006-04
        3 date last_release_date
        4
        Fm: 2006-03-29
        To: 2006-05-23
        5 last_release_date. clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2006_05_23/changes
        2006_06_07 Study Changes Misc.
        1 clinical_study last_release_date
        2
        Fm: 2006-05-23
        To: 2006-06-07
        3 last_release_date clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2006_06_07/changes
        2006_09_29 Study Changes Recruitment, Misc.
        1 clinical_study date
        2
        Fm: 2006-04
        To: 2006-09
        3 date last_release_date
        4
        Fm: 2006-06-07
        To: 2006-09-29
        5 last_release_date clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2006_09_29/changes
        2006_11_08 Study Changes Protocol, Recruitment, Misc.
        1 clinical_study textblock
        2
        Fm: Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Stage IV Melanoma
        To: Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Malignant Melanoma
        3 textblock oversight_info
        4 regulatory_authority United States: Federal Government
        5 oversight_info date
        6
        Fm: 2006-09
        To: 2006-10
        7 date design
        8 condition Stage IV Melanoma
        9 design Open Label
        primary_outcome Response rate based on tumor measurements at 12 weeks
        secondary_outcome Survival at 1, 2, and 5 years from the start of treatment
        10 condition
        11
        Recurrent Melanoma
        Melanoma (Skin)
        12 condition expected_enrollment
        13
        40
        14 expected_enrollment maximum_age
        15
        N/A
        16 maximum_age see_also
        17
        keyword stage IV melanoma
        keyword recurrent melanoma
        18 initial_release_date last_release_date
        19
        Fm: 2006-09-29
        To: 2006-11-08
        20 last_release_date clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2006_11_08/changes
        2007_01_11 Study Changes Misc.
        1 clinical_study oversight_info
        2 Added: regulatory_authority United States: Federal Government
        3 oversight_info last_release_date
        4
        Fm: 2006-11-08
        To: 2007-01-11
        5 last_release_date clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2007_01_11/changes
        2007_01_16 Study Changes Protocol, Misc.
        1 clinical_study oversight_info
        2 Deleted: regulatory_authority United States: Federal Government
        3 oversight_info primary_name
        4
        Fm: biological therapy
        To: biological therapy
        5 primary_name last_release_date
        6
        Fm: 2007-01-11
        To: 2007-01-16
        7 last_release_date clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2007_01_16/changes
        2007_02_20 Study Changes Protocol, Recruitment, Misc.
        1 clinical_study OBJECTIVES:
        2
        Fm: – Determine the safety and possible effectiveness of antineoplastons A10 and AS2-1 in patients with progressive or recurrent stage IV melanoma.
        - Describe response, tolerance to, and side effects of this regimen in these patients.
        To: * Determine the safety and possible effectiveness of antineoplastons A10 and AS2-1 in patients with progressive or recurrent stage IV melanoma.
        * Describe response, tolerance to, and side effects of this regimen in these patients.
        3
        Fm: DISEASE CHARACTERISTICS:
        To: DISEASE CHARACTERISTICS:
        4
        Fm: – Histologically confirmed stage IV melanoma that is recurrent or progressing and unlikely to respond to existing therapy
        - Measurable disease by MRI or CT scan
        To: * Histologically confirmed stage IV melanoma that is recurrent or progressing and unlikely to respond to existing therapy
        * Measurable disease by MRI or CT scan
        5
        Fm: Age:
        To: Age: 6
        Fm: – 18 and over
        To: * 18 and over
        7
        Fm: Performance status:
        To: Performance status:
        8
        Fm: – Karnofsky 60-100%
        To: * Karnofsky 60-100%
        9
        Fm: Life expectancy:
        To: Life expectancy:
        10
        Fm: – At least 2 months
        To: * At least 2 months
        11
        Fm: Hematopoietic:
        To: Hematopoietic:
        12
        Fm: – WBC at least 2,000/mm3
        - Platelet count at least 50,000/mm3
        To: * WBC at least 2,000/mm3
        * Platelet count at least 50,000/mm3
        13
        Fm: Hepatic:
        To: Hepatic:
        14
        Fm: – Bilirubin no greater than 2.5 mg/dL
        - SGOT and SGPT no greater than 5 times the upper limit of normal
        - No hepatic insufficiency
        To: * Bilirubin no greater than 2.5 mg/dL
        * SGOT and SGPT no greater than 5 times the upper limit of normal
        * No hepatic insufficiency
        15
        Fm: Renal:
        To: Renal:
        16
        Fm: – Creatinine no greater than 2.5 mg/dL
        - No renal insufficiency
        - No renal conditions that contraindicate high dosages of sodium
        To: * Creatinine no greater than 2.5 mg/dL
        * No renal insufficiency
        * No renal conditions that contraindicate high dosages of sodium
        17
        Fm: Cardiovascular:
        To: Cardiovascular:
        18
        Fm: – No chronic heart failure
        - No uncontrolled hypertension
        - No history of congestive heart failure
        - No other cardiovascular conditions that contraindicate high dosages of sodium
        To: * No chronic heart failure
        * No uncontrolled hypertension
        * No history of congestive heart failure
        * No other cardiovascular conditions that contraindicate high dosages of sodium
        19
        Fm: Pulmonary:
        To: Pulmonary:
        20
        Fm: – No severe lung disease, such as chronic obstructive pulmonary disease
        To: * No severe lung disease, such as chronic obstructive pulmonary disease
        21
        Fm: Other:
        To: Other:
        22
        Fm: – Not pregnant or nursing
        - Fertile patients must use effective contraception during and for 4 weeks after study
        - No serious medical or psychiatric disorders
        - No active infection
        To: * Not pregnant or nursing
        * Fertile patients must use effective contraception during and for 4 weeks after study
        * No serious medical or psychiatric disorders
        * No active infection
        23
        Fm: PRIOR CONCURRENT THERAPY:
        Biologic therapy:
        To: PRIOR CONCURRENT THERAPY:
        Biologic therapy:
        24
        Fm: – At least 4 weeks since prior immunotherapy and recovered
        - No concurrent immunomodulating agents
        To: * At least 4 weeks since prior immunotherapy and recovered
        * No concurrent immunomodulating agents
        25
        Fm: Chemotherapy:
        To: Chemotherapy:
        26
        Fm: – At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered
        - No concurrent antineoplastic agents
        To: * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered
        * No concurrent antineoplastic agents
        27
        Fm: Endocrine therapy:
        To: Endocrine therapy:
        28
        Fm: – Concurrent corticosteroids allowed
        To: * Concurrent corticosteroids allowed
        29
        Fm: Radiotherapy:
        To: Radiotherapy:
        30
        Fm: – At least 8 weeks since prior radiotherapy and recovered (patients with multiple tumors who have received radiotherapy to some, but not all, tumors may be admitted earlier than 8 weeks)
        To: * At least 8 weeks since prior radiotherapy and recovered (patients with multiple tumors who have received radiotherapy to some, but not all, tumors may be admitted earlier than 8 weeks)
        31
        Fm: Surgery:
        To: Surgery:
        32
        Fm: – Recovered from prior surgery
        To: * Recovered from prior surgery
        33
        Fm: Other:
        To: Other:
        34
        Fm: – Prior cytodifferentiating agent allowed
        - No prior antineoplaston therapy
        To: * Prior cytodifferentiating agent allowed
        * No prior antineoplaston therapy
        35 textblock last_release_date
        36
        Fm: 2007-01-16
        To: 2007-02-20
        37 last_release_date clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2007_02_20/changes
        2007_06_04 Study Changes Protocol, Recruitment, Misc.
        1 clinical_study date
        2
        Fm: 2006-10
        To: 2007-04
        3 date last_follow_up_date
        4 last_data_entry_date date
        5 phase_block primary_outcome
        6 measure
        7
        Fm: Response rate based on tumor measurements at 12 weeks
        To: Response rate based on tumor measurements at 12 weeks
        8 measure time_frame
        9 primary_outcome secondary_outcome
        10 measure
        11
        Fm: Survival at 1, 2, and 5 years from the start of treatment
        To: Survival at 1, 2, and 5 years from the start of treatment
        12 measure time_frame
        13 secondary_outcome
        14 enrollment 40
        15 condition healthy_volunteers
        16 patients
        expected_enrollment 40
        expected_enrollment 17
        gender last_release_date
        18
        Fm: 2007-02-20
        To: 2007-06-04
        19 last_release_date clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2007_06_04/changes
        2007_09_20 Study Changes Protocol, Recruitment, Misc.
        1 clinical_study date
        2
        Fm: 2007-04
        To: 2007-09
        3 date primary_name
        4 description textblock
        5 intervention primary_name
        6 description textblock
        7 intervention intervent_type
        8
        Fm: Procedure
        To: Procedure/Surgery
        9 intervent_type primary_name
        10 description textblock
        11 intervention intervent_type
        12
        Fm: Procedure
        To: Procedure/Surgery
        13 intervent_type primary_name
        14 description textblock
        15 intervention intervent_type
        16
        Fm: Procedure
        To: Procedure/Surgery
        17 intervent_type primary_name
        18 description textblock
        19 intervention intervent_type
        20
        Fm: Procedure
        To: Procedure/Surgery
        21 intervent_type primary_name
        22 description textblock
        23 intervention intervent_type
        24
        Fm: Procedure
        To: Procedure/Surgery
        25 intervent_type primary_name
        26 description textblock
        27 intervention intervent_type
        28
        Fm: Procedure
        To: Procedure/Surgery
        29 intervent_type primary_name
        30 description textblock
        31 intervention last_release_date
        32
        Fm: 2007-06-04
        To: 2007-09-20
        33 last_release_date clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2007_09_20/changes
        2007_10_17 Study Changes Protocol, Misc.
        1 clinical_study primary_name
        2
        Intervention/procedure

        Procedure/Surgery

        3 alternative product therapy primary_name
        4
        Fm: cancer prevention intervention
        To: cancer prevention
        5 primary_name intervention
        6

        Procedure/Surgery

        preventive intervention

        7 eligibility last_release_date
        8
        Fm: 2007-09-20
        To: 2007-10-17
        9 last_release_date clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2007_10_17/changes
        2007_10_19 Study Changes Protocol, Misc.
        1 clinical_study primary_name
        2
        Fm: cancer prevention
        To: complementary or alternative medical procedure
        3 primary_name
        4
        complementary and alternative therapy

        Procedure/Surgery

        5 differentiation therapy intervention
        6

        Procedure/Surgery

        preventive intervention

        7 eligibility last_release_date
        8
        Fm: 2007-10-17
        To: 2007-10-19
        9 last_release_date clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2007_10_19/changes
        2007_10_29 Study Changes Protocol, Misc.
        1 clinical_study primary_name
        2
        Intervention/procedure

        Procedure/Surgery

        3 alternative product therapy primary_name
        4
        biological therapy

        Procedure/Surgery

        biologically based therapies

        Procedure/Surgery

        complementary or alternative medical procedure

        Procedure/Surgery

        5 differentiation therapy last_release_date
        6
        Fm: 2007-10-19
        To: 2007-10-25
        7 last_release_date clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2007_10_29/changes
        2007_11_06 Study Changes Protocol, Misc.
        1 clinical_study primary_name
        2
        Fm: alternative product therapy
        To: antineoplastons therapy
        3 primary_name last_release_date
        4
        Fm: 2007-10-25
        To: 2007-11-06
        5 last_release_date clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2007_11_06/changes
        2007_11_16 Study Changes Recruitment, Misc.
        1 clinical_study date
        2 1998-08
        3 date last_release_date
        4
        Fm: 2007-11-06
        To: 2007-11-16
        5 last_release_date clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2007_11_16/changes
        2007_12_26 Study Changes Protocol, Recruitment, Misc.
        1 clinical_study date
        2
        Fm: 1998-08
        To: 1996-03
        3 date last_follow_up_date
        4
        primary_compl_date
        type=”Anticipated”

        date
        2008-01
        primary_compl_date
        5 phase_block time_frame
        6 safety_issue No
        7 primary_outcome time_frame
        8 safety_issue No
        9 secondary_outcome last_release_date
        10
        Fm: 2007-11-16
        To: 2007-12-25
        11 last_release_date clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2007_12_26/changes
        2008_01_11 Study Changes Recruitment, Misc.
        1 clinical_study date
        2
        Fm: 2007-09
        To: 2008-01
        3 date last_release_date
        4
        Fm: 2007-12-25
        To: 2008-01-10
        5 last_release_date clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2008_01_11/changes
        2008_04_09 Study Changes Recruitment, Misc.
        1 clinical_study date
        2
        Fm: 2008-01
        To: 2008-04
        3 date last_release_date
        4
        Fm: 2008-01-10
        To: 2008-04-09
        5 last_release_date clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2008_04_09/changes
        2008_04_18 Study Changes Recruitment status, Misc.
        1 clinical_study oversight_info
        2. regulatory_authority United States: Federal Government
        3 oversight_info status
        4
        Fm: Recruiting
        To: Active, not recruiting
        5 status last_release_date
        6
        Fm: 2008-04-09
        To: 2008-04-18
        7last_release_date clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2008_04_18/changes
        2008_05_26 Study Changes Protocol, Misc.
        1 clinical_study intervention
        2
        intervention intervent_type Procedure/Surgery
        intervent_type primary_name antineoplastons therapy
        primary_name description text block description intervent_type Procedure/Surgery
        intervent_type primary_name Wa aoaidifferentiation therapy
        primary_name description textblock. description interventions
        3 eligibility last_release_date
        4
        Fm: 2008-04-18
        To: 2008-05-23
        5 last_release_date. clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2008_05_26/changes
        2008_07_23 Study Changes Misc.
        1 clinical_study design
        2 number_of_arms 1
        3 primary_outcome secondary_outcome
        4 enrollment
        5 enrollment type=”Anticipated”
        6 40 last_release_date
        7
        Fm: 2008-05-23
        To: 2008-07-23
        8 last_release_date. clinical_study
        http://clinicaltrials.gov/archive/NCT00003509/2008_07_23/changes
        2009_05_26 Study Changes Recruitment status, Recruitment, Misc.
        1 clinical_study study_id
        2
        is_fda_regulated Yes
        is_section_801 Yes
        delayed_posting No
        resp_party name_title Stanislaw R. Burzynski
        name_title organization Burzynski Clinic
        organization resp_party
        Fm: Active, not recruiting
        To: Completed
        status date
        Fm: 2008-04
        To: 2009-05
        date
        Fm: 2008-01
        To: 2005-02
        last_release_date
        Fm: 2008-07-23
        To: 2009-05-23
        http://clinicaltrials.gov/archive/NCT00003509/2009_05_26/changes
        So, we know the “completed” date is:

        2009-05-23 (5/23/2009)

        To put this in perspective, the below study done in 2006, was NOT published until about 7 years later, in 2013

        2/13/2013 – The frequency, cost, and clinical outcomes of HYPERNATREMIA in patients hospitalized to a comprehensive CANCER center
        http://www.ncbi.nlm.nih.gov/m/pubmed/23404230
        Over 3 month period in 2006 re 3,446 patients, most of the HYPERNATREMIA (90 %) was acquired during hospital stay

        Division of Internal Medicine, UT MD Anderson Cancer Center, Houston, TX, USA

        Department of General Internal Medicine, University of Texas MD Anderson Cancer Center

        Division of Endocrinology, Mayo Clinic

        Support Care Cancer. 2013 Feb 13. [Epub ahead of print]

        Supportive Care in Cancer
        February 2013

        DOI
        10.1007/s00520-013-1734-6
        http://link.springer.com/article/10.1007%2Fs00520-013-1734-6
        “Many more are still active or have been withdrawn.”

        “MANY MORE” ?

        Let’s NOT take YOUR word for it, since you are BIASED

        Let’s look at “FACTS” which are supported by citation(s), reference(s), and / or link(s)

        1 – Not Yet Recruiting
        (OPEN)(Phase 3)
        1 – CLOSED
        2 – WITHDRAWN
        (Withdrawn due to slow enrollment)
        7 – WITHDRAWN
        (This study has been withdrawn prior to enrollment)
        (9=WITHDRAWN)
        10 – Recruiting
        (10=OPEN)
        40 – Active, not recruiting -
        (40=CLOSED)
        61 =TOTAL

        1 – Not Yet Recruiting + 10 – Recruiting -
        (11=OPEN)
        2 – WITHDRAWN
        (Withdrawn due to slow enrollment)
        7 – WITHDRAWN
        (This study has been withdrawn prior to enrollment)
        (9=WITHDRAWN)
        40 – Active, not recruiting -
        (40=CLOSED)
        (1=COMPLETED)
        61=TOTAL

        1 – Not Yet Recruiting -
        (1=OPEN)
        10 Active -
        (10=OPEN)
        (9=WITHDRAWN)
        25 CLOSED +15 CLOSED -
        (40=CLOSED)
        (1= COMPLETED)
        61=TOTAL

        10 – Recruiting
        (OPEN)
        1 Not Yet Recruiting / 10 Recruiting -
        (11=OPEN)
        (9=WITHDRAWN)
        40 – Active, not recruiting
        (40=CLOSED)
        (1= COMPLETED)
        61=TOTAL

        11=1 Not Yet Recruiting / 10 Recruiting -
        (11=OPEN)
        (9=WITHDRAWN)
        (40=CLOSED)
        (1= COMPLETED)
        61=TOTAL

        “Many more are still active”

        So, your definition of “MANY MORE are still ACTIVE”
        = 11 OPEN (ACTIVE)

        “or have been withdrawn.”

        2 – WITHDRAWN
        (Withdrawn due to slow enrollment)
        7 – WITHDRAWN
        (This study has been withdrawn prior to enrollment)
        = 9 WITHDRAWN

        “This is a pitiful number.”

        20 = “a PITIFUL NUMBER”

        “Please do not repeat those same statistics again.”

        1 – Not Yet Recruiting
        (1=OPEN)(Phase 3)
        10 – Recruiting
        (10=OPEN)
        11=TOTAL

        1 – Not Yet Recruiting + 10 – Recruiting -
        (11=OPEN)
        11=TOTAL

        1 – Not Yet Recruiting -
        (1=OPEN)
        10 Active -
        (10=OPEN)
        11=TOTAL

        10 – Recruiting
        (OPEN)
        1 Not Yet Recruiting / 10 Recruiting -
        (11=OPEN)
        11=TOTAL

        11=1 Not Yet Recruiting / 10 Recruiting -
        (11=OPEN)
        11=TOTAL

        “Simply conducting a study and labeling it as perpetually “active” (but closed) is not a result.”

        The below 1 st link: 10 Active (Open):
        http://cancer.gov/clinicaltrials/search/results?protocolsearchid=11475951
        1. Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer
        Phase: Phase II
        Type: Treatment
        Status: Active
        Age: 6 months and over
        Sponsor: Other
        Protocol IDs: CDR0000066485, BC-AD-2, NCT00003453

        2. Antineoplaston Therapy in Treating Patients With Brain Tumors
        Phase: Phase II
        Type: Treatment
        Status: Active
        Age: 18 and over
        Sponsor: Other
        Protocol IDs: CDR0000066489, BC-BT-9, NCT00003457

        3. Antineoplaston Therapy in Treating Children With Brain Tumors
        Phase: Phase II
        Type: Treatment
        Status: Active
        Age: 6 months to 17 years
        Sponsor: Other
        Protocol IDs: CDR0000066490, BC-BT-10, NCT00003458

        4. Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma
        Phase: Phase II
        Type: Treatment
        Status: Active
        Age: 6 months to 17 years
        Sponsor: Other
        Protocol IDs: CDR0000066504, BC-BT-13, NCT00003468

        5. Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma
        Phase: Phase II
        Type: Treatment
        Status: Active
        Age: 18 and over
        Sponsor: Other
        Protocol IDs: CDR0000066507, BC-BT-15, NCT00003470

        6. Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
        Phase: Phase II
        Type: Treatment
        Status: Active
        Age: 18 and over
        Sponsor: Other
        Protocol IDs: CDR0000066510, BC-BT-18, NCT00003473

        7. Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors
        Phase: Phase II
        Type: Treatment
        Status: Active
        Age: 18 and over
        Sponsor: Other
        Protocol IDs: CDR0000066512, BC-BT-21, NCT00003475

        8. Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors
        Phase: Phase II
        Type: Treatment
        Status: Active
        Age: 6 months to 17 years
        Sponsor: Other
        Protocol IDs: CDR0000066513, BC-BT-22, NCT00003476

        9. Antineoplaston Therapy in Treating Children With Visual Pathway Glioma
        Phase: Phase II
        Type: Treatment
        Status: Active
        Age: 6 months to 17 years
        Sponsor: Other
        Protocol IDs: CDR0000066514, BC-BT-23, NCT00003477

        10. Antineoplaston Therapy in Treating Patients With Residual or Recurrent Anaplastic Astrocytoma
        Phase: Phase II
        Type: Treatment
        Status: Active
        Age: 18 and over
        Sponsor: Other
        Protocol IDs: CDR0000066585, BC-BT-8, NCT00003537

        From the Securities and Exchange Commission (SEC) filings we can find these 10 “MANY MORE are still ACTIVE” (OPEN) trials:

        Burzynski Clinical Trials (The SEC filings):
        https://stanislawrajmundburzynski.wordpress.com/2013/04/11/burzynski-clinical-trials-2/
        11/25/1997 – FORM 10-SB
        http://pdf.secdatabase.com/2573/0000950110-97-001598.pdf
        11/25/1997 – Company sponsoring 72 Phase II clinical trials conducted pursuant to INDs filed with FDA which are currently ongoing

        1. AD-2 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN PATIENTS WITH CARCINOMA OF THE ADRENAL GLAND
        7/20/96 – Revised
        9/28/96 – Revised
        4/14/97 – Revised

        2. BT-9 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN PATIENTS WITH BRAIN TUMORS
        11 40
        7/11/96 – Revised
        9/28/96 – Revised
        4/14/97 – Revised

        3. BT-10 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN CHILDREN WITH BRAIN TUMORS
        5 40
        7/11/96 – Revised
        9/28/96 – Revised
        4/14/97 – Revised

        4. BT-13 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN CHILDREN WITH LOW GRADE ASTROCYTOMA
        7 40
        7/11/96 – Revised
        9/28/96 – Revised
        4/14/97 – Revised
        9/5/97 – Revised

        5. BT-15 PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 IN ADULT PATIENTS WITH ANAPLASTIC ASTROCYTOMA
        7/26/96 – Revised
        10/4/96 – Revised
        4/14/97 – Revised
        9/5/97 – Revised

        6. BT-18 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN ADULT PATIENTS WITH MIXED GLIOMA
        12 40
        7/26/96 – Revised
        10/4/96 – Revised
        12/9/96 – Revised
        4/14/97 – Revised

        7. BT-21 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN ADULT PATIENTS WITH PRIMARY MALIGNANT BRAIN
        TUMORS
        19 40
        9/5/95 – Partially Amended, pg.
        9/10/96 – Revised
        4/14/97 – Revised
        8/25/97 – Revised

        8. BT-22 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN CHILDREN WITH PRIMARY MALIGNANT BRAIN
        TUMORS
        4 40
        11/5/97 – Partially Amended, pg.
        4/14/97 – Revised
        9/10/97 – Revised

        9. BT-23 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 INFUSIONS IN CHILDREN WITH VISUAL PATHWAY
        GLIOMA
        2 40
        5/22/96 -
        11/18/96 – Revised
        4/14/97 – Revised

        10. BT-8 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN PATIENTS WITH ANAPLASTIC ASTROCYTOMA
        9 40
        4/14/97 – Revised
        9/15/97 – Revised

        Burzynski Clinical Trials (The SEC filings):
        https://stanislawrajmundburzynski.wordpress.com/2013/04/11/burzynski-clinical-trials-2/
        Certain prospective protocols which have reached a Milestone as of May 1, 2012

        The results of Protocols
        10. BT-08
        2. BT-09
        3. BT-10
        4. BT-13
        5. BT-15
        6. BT-18
        7. BT-21
        8. BT-22
        9. BT-23
        are set forth below (as of May 1, 2012)

        1. Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer
        Adrenocortical Carcinoma
        Drug: antineoplaston A10
        Drug: antineoplaston AS2-1
        Phase II / Phase 2
        ACTIVE
        Age 6 months and over
        Protocol IDs
        CDR0000066485
        BC-AD-2, NCT00003453
        http://cancer.gov/clinicaltrials/BC-AD-2
        2. Antineoplaston Therapy in Treating Patients With Brain Tumors
        Brain and Central Nervous System Tumors
        Drug: antineoplaston
        Drug: antineoplaston AS2-1
        Phase II / Phase 2
        ACTIVE
        Age 18 and over
        Protocol IDs
        CDR0000066489
        BC-BT-9, NCT00003457
        http://cancer.gov/clinicaltrials/BC-BT-9
        · Protocol BT-09, involving the study of Antineoplastons A10 and AS2-1 in patients with brain tumors

        BT-09 – Protocol #
        40 – Patients Accrued
        28 – Evaluable Patients
        4 / 14.3% – # and % of Patients Showing Complete Response
        5 / 17.9% – # and % of Patients Showing Partial Response
        13 / 46.4% – # and % of Patients Showing Stable Disease
        6 / 21.4% – # and % of Patients Showing Progressive Disease

        3. Antineoplaston Therapy in Treating Children With Brain Tumors
        Brain and Central Nervous System Tumors
        Drug: antineoplaston A10
        Drug: antineoplaston AS2-1
        Phase II / Phase 2
        ACTIVE
        Age 6 months to 17 years
        Protocol IDs
        CDR0000066490
        BC-BT-10, NCT00003458
        http://cancer.gov/clinicaltrials/BC-BT-10
        · Protocol BT-10, involving the study of Antineoplastons A10 and AS2-1 in children with brain tumors

        BT-10 – Protocol #
        30 – Patients Accrued
        22 – Evaluable Patients
        3 / 13.6% – # and % of Patients Showing Complete Response
        1 / 4.5% – # and % of Patients Showing Partial Response
        7 / 31.8% – # and % of Patients Showing Stable Disease
        11 / 50.0% – # and % of Patients Showing Progressive Disease

        4. Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma
        Brain and Central Nervous System Tumors
        Drug: antineoplaston A10
        Drug: antineoplaston AS2-1
        Phase II / Phase 2
        ACTIVE
        Age 6 months to 17 years
        Protocol IDs
        CDR0000066504
        BC-BT-13, NCT00003468
        http://cancer.gov/clinicaltrials/BC-BT-13
        · Protocol BT-13, involving the study of Antineoplastons A10 and AS2-1 in children with low grade astrocytoma, a type of PMBT

        BT-13 – Protocol #
        17 – Patients Accrued
        14 – Evaluable Patients
        6 / 42.9% – # and % of Patients Showing Complete Response
        1 / 7.1% – # and % of Patients Showing Partial Response
        5 / 35.7% – # and % of Patients Showing Stable Disease
        2 / 14.3% – # and % of Patients Showing Progressive Disease

        5. Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma
        Brain and Central Nervous System Tumors
        Drug: antineoplaston A10
        Drug: antineoplaston AS2-1
        Phase II / Phase 2
        ACTIVE
        Age 18 and over
        Protocol IDs
        CDR0000066507
        BC-BT-15, NCT00003470
        http://cancer.gov/clinicaltrials/BC-BT-15
        · Protocol BT-15, involving the study of Antineoplastons A10 and AS2-1 in adult patients with anaplastic astrocytoma, a type of PMBT

        BT-15 – Protocol #
        27 – Patients Accrued
        20 – Evaluable Patients
        3 / 15.0% – # and % of Patients Showing Complete Response
        2 / 10.0% – # and % of Patients Showing Partial Response
        9 / 45.0% – # and % of Patients Showing Stable Disease
        6 / 30.0% – # and % of Patients Showing Progressive Disease

        6. Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
        Brain and Central Nervous System Tumors
        Drug: antineoplaston A10
        Drug: antineoplaston AS2-1
        Phase II / Phase 2
        ACTIVE
        Age 18 and over
        Protocol IDs
        CDR0000066510
        BC-BT-18, NCT00003473
        http://cancer.gov/clinicaltrials/BC-BT-18
        Protocol BT-18, involving a study of Antineoplastons A10 and AS2-1 in the treatment of “mixed glioma,” a type of PMBT

        BT-18 – Protocol #
        20 – Patients Accrued
        13 – Evaluable Patients
        3 / 23.1% – # and % of Patients Showing Complete Response
        1 / 7.7% – # and % of Patients Showing Partial Response
        3 / 23.1% – # and % of Patients Showing Stable Disease
        6 / 46.2% – # and % of Patients Showing Progressive Disease

        7. Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors
        Brain and Central Nervous System Tumors
        Drug: antineoplaston A10
        Drug: antineoplaston AS2-1
        Phase II / Phase 2
        ACTIVE
        Age 18 and over
        Protocol IDs
        CDR0000066512
        BC-BT-21, NCT00003475
        http://cancer.gov/clinicaltrials/BC-BT-21
        · Protocol BT-21, involving the study of Antineoplastons A10 and AS2-1 in adults with primary malignant brain tumors

        BT-21 – Protocol #
        40 – Patients Accrued
        23 – Evaluable Patients
        2 / 8.7% – # and % of Patients Showing Complete Response
        2 / 8.7% – # and % of Patients Showing Partial Response
        9 / 39.1% – # and % of Patients Showing Stable Disease
        10 / 43.5% – # and % of Patients Showing Progressive Disease

        8. Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors
        Brain and Central Nervous System Tumors
        Drug: antineoplaston A10
        Drug: antineoplaston AS2-1
        Phase II / Phase 2
        ACTIVE
        Age 6 months to 17 years
        Protocol IDs
        CDR0000066513
        BC-BT-22, NCT00003476
        http://cancer.gov/clinicaltrials/BC-BT-22
        · Protocol BT-22, involving a study of Antineoplastons A10 and AS2-1 in children with primary malignant brain tumors

        BT-22 – Protocol #
        40 – Patients Accrued
        24 – Evaluable Patients
        1 / 4.2% – # and % of Patients Showing Complete Response
        3 / 12.5% – # and % of Patients Showing Partial Response
        9 / 37.5% – # and % of Patients Showing Stable Disease
        11 / 45.8% – # and % of Patients Showing Progressive Disease

        9. Antineoplaston Therapy in Treating Children With Visual Pathway Glioma
        Drug: antineoplaston A10
        Drug: antineoplaston AS2-1
        Phase II / Phase 2
        ACTIVE
        Age 6 months to 17 years
        Protocol IDs
        CDR0000066514
        BC-BT-23, NCT00003477
        http://cancer.gov/clinicaltrials/BC-BT-23
        (· Protocol BT-23, involving a study of Antineoplastons A10 and AS2-1 in children with visual pathway glioma)

        BT-23- Protocol #
        16 – Patients Accrued
        12 – Evaluable Patients
        3 / 25% – # and % of Patients Showing Complete Response
        2 / 16.7% – # and % of Patients Showing Partial Response
        6 / 50.0% – # and % of Patients Showing Stable Disease
        1 / 8.3% – # and % of Patients Showing Progressive Disease

        10. Antineoplaston Therapy in Treating Patients With Residual or Recurrent Anaplastic Astrocytoma
        Brain and Central Nervous System Tumors
        Drug: antineoplaston A10
        Drug: antineoplaston AS2-1
        Recruiting
        Phase II / Phase 2
        ACTIVE
        Age 18 and over
        Protocol IDs
        CDR0000066585
        BC-BT-8, NCT00003537
        http://cancer.gov/clinicaltrials/BC-BT-8
        · Protocol BT-08, involving the study of Antineoplastons A10 and AS2-1 in patients with anaplastic astrocytoma

        BT-08 – Protocol #
        19 – Patients Accrued
        14- Evaluable Patients
        4 / 28.6% – # and % of Patients Showing Complete Response
        0 / 0.0% – # and % of Patients Showing Partial Response
        6 / 42.9% – # and % of Patients Showing Stable Disease
        4 / 28.6% – # and % of Patients Showing Progressive Disease

        “Please provide a source showing any published studies.”

        Drugs in R and D (Drugs in Research and Development)

        2003 – Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma:

        a preliminary report
        http://www.ncbi.nlm.nih.gov/m/pubmed/12718563
        Drugs R D. 2003;4(2):91-101

        2004 – Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma :

        a preliminary report
        http://www.ncbi.nlm.nih.gov/m/pubmed/15563234
        Drugs R D. 2004;5(6):315-26

        Integrative Cancer Therapies

        6/2005 – Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1
        http://www.ncbi.nlm.nih.gov/m/pubmed/15911929
        Integr Cancer Ther. 2005 Jun;4(2):168-77

        3/2006 – Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma
        http://www.ncbi.nlm.nih.gov/m/pubmed/16484713
        Integr Cancer Ther. 2006 Mar;5(1):40-7

        2007 – Recent clinical trials in diffuse intrinsic brainstem glioma

        Review Article
        http://www.cancer-therapy.org/CT/v5/B/HTML/42._Burzynski,_379-390.html
        Cancer Therapy Vol 5, 379-390, 2007
        http://www.burzynskiclinic.com/images/stories/Publications/1252.pdf
        “I” have NOT conducted ANY studies because “I” am NOT Burzynski; a fact you would known if you had “researched” it

        “As far as I can tell, I have no way of knowing this.”

        THAT is why it’s called “research”

        “You don’t sign your name anywhere, blog under a pseudonym, and have a blank “About” page.”

        THAT is because some of “The Skeptics” are from irrational island, so I take the @_JosephineJones approach

        “Since the blog’s name is “stanislawrajmundburzynski,” I’m sure you will forgive my confusion.”

        THAT is because I wanted to apply the military policy of “K.I.S.S.” (Keep It Simple, Stupid), for “The Skeptics”

        “I wouldn’t think this was a big deal, except you seem to use my incorrect pronoun as an excuse to disregard large portions of my text.”

        Your pal “Orac” posted:

        “I also know that … Didymus Judas Thomas”

        “(whose identity I’m probably about 75% sure of…”
        http://scienceblogs.com/insolence/2013/04/19/eric-merola-issuing-bogus-dmca-takedown-notices-against-critics-of-stanislaw-burzynski/
        If you really thought Burzynski; a 70 year old, would be engaging you at ridiculous hours, or Merola, or anyone working for either of them…

        “I’m sorry I confused you with someone else, but that has no bearing on the truth of my arguments.”

        What “truth” ?

        “And to be clear, I did not think you were Dr. Burzynski himself.”

        “When I referred to “you,” I mean “you” in the general sense of your company.”

        “Your company”

        Wrong again

        “If you are not affiliated, then again, that’s just a mistake.”

        As I commented on Forbes:

        As former President Ronald Reagan used to say:

        “Well, there you go again.”

        Let me make this perfectly clear and unambiguous as I can.

        1. I am NOT Dr. Stanislaw R. Burzynski, I have never worked for him, I have never met him.

        2. I am NOT AstroTurfWatch.

        3. I am NOT Eric Merola, I have never worked for him, I have never met him.

        4. I am NOT Randy Hinton, I have never met him, this article is the first place I have seen his name.
        http://www.forbes.com/sites/peterlipson/2013/04/19/a-film-producer-a-cancer-doctor-and-their-critics
        This link reflects:

        11/25/1997 – Filing Date: FORM 10-SB

        11/25/1997 – Company sponsoring 72 Phase II clinical trials conducted pursuant to INDs filed with FDA which are currently ongoing

        And it lists the 72 clinical trials

        “Those are not results.”

        “Those are ongoing studies.”

        “I am asking for results of concluded studies.”

        “I don’t know why these are difficult to procure.”

        So … you are NOT a researcher?

        “As I understand it, Dr. Burzynski has been performing trials for nearly forty years, and has never published results demonstrating the efficacy of his treatment in a peer-reviewed journal.”

        WOW

        “Dr. Burzynski has been performing trials for nearly forty years…”

        Where did you come up with THAT doozy?

        Let’s see what we find here, shall we?

        Burzynski Clinical Trials (The SEC filings):
        https://stanislawrajmundburzynski.wordpress.com/2013/04/11/burzynski-clinical-trials-2/
        2/28/2010 Form 10-K for fiscal year ended:
        http://www.sec.gov/Archives/edgar/data/0000724445/000110465910031825/0001104659-10-031825-index.htm
        Company began Phase II clinical studies in 1994 with 4 studies

        “If I am mistaken, please direct me to the publication.”

        How about THESE publications?

        “Trial results are not always publicly available, even after a clinical trial ends:”
        http://www.nlm.nih.gov/services/ctresults.html
        U.S. National Library of Medicine National Institutes of Health

        National Cancer Institute (NCI) at the National Institutes of Health (NIH)

        Cancer Clinical Trials

        15. What happens when a clinical trial is over?

        “The results of clinical trials are OFTEN published in peer-reviewed scientific journals”

        ” … WHETHER OR NOT the results are published in a peer-reviewed scientific journal … “
        http://m.cancer.gov/topics/factsheets/clinical-trials
        This makes it clear that clinical trial results “are OFTEN” published, but sometimes they are “NOT” published “in a peer-reviewed scientific journal”

        The Declaration of Helsinki does NOT indicate WHEN the final results of human clinical trials MUST be published:

        World Medical Association
        http://www.wma.net/en/30publications/10policies/b3
        PDF:
        http://www.wma.net/en/30publications/10policies/b3/17c.pdf
        PDF:
        http://www.who.int/bulletin/archives/79(4)373.pdf
        National Institutes of Health-HISTORY:
        http://history.nih.gov/research/downloads/helsinki.pdf
        “Please stop listing registration for studies as if that were a result.”

        What evidence do you have that Burzynski has or has NOT attempted to:

        “receive money from federal and private grants, tax exemption, and private donations.”?

        “I do not suggest that he has not applied for grants, and I am sure he has accepted donations.”

        “However, it appears he has not received grant money.”

        “As I said, being unable to procure grants is evidence of an ineffective or unproven treatment, not evidence of persecution.”

        And your citation(s), reference(s), and / or link(s) which support your statement are?

        “Furthermore, he cannot have tax-exempt status, because his clinics turn a profit.”

        He has “clinics,” plural ?

        Well, at least you seem to differ from “The Skeptics” who keep insisting that the clinical trials turn a profit, as opposed to the non- clinical trial operations:

        Burzynski (The SEC filings):
        https://stanislawrajmundburzynski.wordpress.com/2013/04/16/burzynski-the-sec-filings
        What evidence do you have that Burzynski has or has NOT attempted

        “to make an investment or get other investors for real science.?”

        Have you read his Securities and Exchange Commission filings like I have?

        “Again, it feels like you are deliberately misreading me.”

        Nope, I read this:

        “If you intend to profit off an approved drug, you should be willing to make an investment or get other investors for real science.”

        If you review the Securities and Exchange Commission (SEC) filings you will find BRZY:OTC US stock for Burzynski

        “I never suggested he had not made these attempts.”

        “I do not care what he has “tried” to do.”

        “The fact is he has not done so.”

        So, you are wrong because BRZY exists

        “As I have said, passing the cost on to his patients is not an acceptable alternative.”

        THAT is your opinion, and you are entitled to your opinion, but that’s all it is

        “It seems he has turned to both private and public sources and not received support for his unproven treatments, so instead he draws the support from the most vulnerable.”

        Maybe you and “The Skeptics” can help raise the necessary funding

        FALSE: Burzynski does NOT charge for antineoplastons

        “According to the ACS, “Antineoplastons are given by mouth, injection into a vein or muscle, and by other routes.”

        “The treatment usually lasts from 8 – 12 months.”

        “Treatment can cost from $7,000 to $9,500 per month or more . . . .”

        “Here is a reprint of parts of a page curiously removed from the internet, telling the story of one patient whose Burzynski trial drugs cost in excess of $4k a month each.”

        “Either way, the point is moot.”

        “In order to enroll in these studies, you must receive your cancer treatment from the Burzynski Clinic, and that clinic charges around $7500 a month for chemotherapy for a typical patient.”

        And for comparison purposes, you can refer to THIS:

        Burzynski: Costs of Cancer treatments:
        https://stanislawrajmundburzynski.wordpress.com/2013/04/25/burzynski-costs-of-cancer-treatments
        “I would like to note that you failed to respond in any substantive fashion to the claims that:”

        “1. There are no peer-reviewed results of Dr. Burzynski’s many trials.”

        Michael, what relevance does your question have after reading THESE?

        FAQ: Clinical Trial Results:
        https://stanislawrajmundburzynski.wordpress.com/2013/04/26/burzynski-faq-clinical-trial-results/
        What happens when a clinical trial is over?:
        https://stanislawrajmundburzynski.wordpress.com/2013/04/25/burzynski-what-happens-when-a-clinical-trial-is-over
        Declaration of Helsinki:
        https://stanislawrajmundburzynski.wordpress.com/2013/04/25/burzynski-declaration-of-helsinki
        “2. At least 61 trials have been registered.”

        So ?

        “3. The evidence you presented for a conspiracy against Dr. Burzynski’s work is nothing of the sort.”

        I would like to note that you failed to respond in any substantive fashion to the claims that I provided, as evidenced by your response:

        “Your evidence of a scientific conspiracy against your work is not evidence at all.”

        “It consists of a letter written by Burzynski and a disorganized list of links showing various NCI agreements spanning more than three decades.”

        (c0nc0rdance video)

        6:41-Conspiracy

        POSITIVE ?

        Let’s review the links I provided, shall we?

        FACT: See these 2 links:
        http://burzynskimovie.com/images/stories/transcript/Documents/BurzynskiTriesToExposeNCI.pdf

        http://stanislawrajmundburzynski.wiki-site.com/index.php/Main_Page
        10/2/1991
        11/2/1993
        3/1/1994
        3/23/1994
        4/19/1994
        1/31/1995
        4/3/1995
        8/23/1995
        9/19/1995
        10/5/1995
        10/25/1995
        10/27/1995

        10/2/1991-10/27/1995 is NOT

        “spanning more than three decades.”

        And now you can add to those:

        “The Skeptics:” Your problem is, Wikipedia IS censored:
        https://stanislawrajmundburzynski.wordpress.com/2013/04/14/the-skeptics-your-problem-is-wikipedia-is-censored
        Wikipedia, what’s your motivation?:
        https://stanislawrajmundburzynski.wordpress.com/2013/05/02/wikipedia-whats-your-motivation/
        Forbes censors Peter Lipson “Speech is best countered by more speech” article comments:
        https://stanislawrajmundburzynski.wordpress.com/2013/04/23/forbes-censors-peter-lipson-speech-is-best-countered-by-more-speech-article-comments/
        Dr. Peter A. Lipson and / or his censor(s) is a coward: Critiquing A Film Producer, A Cancer Doctor, And Their Critics:
        https://stanislawrajmundburzynski.wordpress.com/2013/04/26/dr-peter-a-lipson-and-or-his-censors-is-a-coward-critiquing-a-film-producer-a-cancer-doctor-and-their-critics
        Forbes Learns a Lesson, but Not the Right One: Censorship and Bias re: A Film Producer, A Cancer Doctor, And Their Critics:
        https://stanislawrajmundburzynski.wordpress.com/2013/05/05/forbes-learns-a-lesson-but-not-the-right-one-censorship-and-bias-re-a-film-producer-a-cancer-doctor-and-their-critics/
        “Orac” and the “Oracolytes” Cult of Misinformation:
        https://stanislawrajmundburzynski.wordpress.com/2013/04/29/orac-and-the-oracolytes-cult-of-misinformation/
        Orac, a lilady, the Oracolytes: “The Skeptic” Burzynski Critics: A Film Producer, A Cancer Doctor, And Their Critics:
        https://stanislawrajmundburzynski.wordpress.com/2013/05/01/orac-a-lilady-the-oracolytes-the-skeptic-burzynski-critics-a-film-producer-a-cancer-doctor-and-their-critics/
        Critiquing: Is Eric Merola issuing bogus DMCA takedown notices against critics of Stanislaw Burzynski?:
        https://stanislawrajmundburzynski.wordpress.com/2013/05/07/critiquing-is-eric-merola-issuing-bogus-dmca-takedown-notices-against-critics-of-stanislaw-burzynski/
        “3a. Specifically that Dr. Burzynski used inappropriate definitions for “advanced cancer.””

        I’ve said it before and I’ll say it again:

        THAT is your opinion, and you are entitled to your opinion, but that’s all it is

        You will need to do better than this with what Americans consider appropriate “citation(s),” “reference(s), and / or “link(s)”

        “4. Eric Merola has on a number of occasions abused libel and copyright law to suppress criticism online.”

        I’ve said it before and I’ll say it again:

        THAT is your opinion, and you are entitled to your opinion, but that’s all it is until such time as it may be proven in a court of law

        My review of C0nc0rdance:
        https://stanislawrajmundburzynski.wordpress.com/2013/03/23/my-review-of-c0nc0rdance

  3. I will not even attempt to read your 6000+ word rant, which is so poorly formatted that I cannot even distinguish your words from words you are quoting.

    I will however point out for the third time that just because a study is no longer actively recruiting does not mean it produced any results. You can close a trial and then open a new one at no cost. The Burzynski clinic has never published a single in vivo study supporting the effectiveness of antineoplastons to treat anything. You clearly do not have even a basic understanding of this process, and thus continue to repeat inane nonsense.

    This conversation is over. I hope when you turn twelve years old, you will understand why I am so frustrated.

    • This is the response one would expect from one of “The Skeptics”
      Your “pal” “Orac” frequently posts epistles of verbosity, and I take the time to read them
      Yet you, a Skeptic, can NOT handle the same thing in return, and seem unable to grasp the concept of why “quotation” marks are put at the beginning and end of certain sentences and words
      Once you’ve grown up and been around half a century, let me know

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s